Our experience of bromfenac-containing NSAID use in patients after cataract surgery

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Postoperative cystoid macular edema is an autoimmune reaction due to the blood-retinal barrier breakdown occurring at anterior segment inflammation. Aim: To analyze the effectiveness of various anti-inflammatory therapeutic schemes used in cataract surgery. Materials and methods. Phacoemulsification using similar consumables had been performed in 792 patients (932 eyes). They were divided into three groups: 1st group included patients receiving 1 to 3 dexamethasone (0.3 ml) and mesatone (0.1 ml) injections and Tobradex eye drops starting with 5 times a day for 4-5 weeks and then tapering (356 eyes); 2nd group (331 eyes) used eye drops of levofloxacin 0.5% solution and dexamethasone; and the 3rd group (325 eyes) in which instillations of ofloxacine and dexamethasone were combined with 0.09% eye drops solution of bromfenac (Broxinac) eye drops, the latter being prescribed QD for 2 days before and 16 days after surgery. Results. Treatment outcomes were less favorable in Group 1 (complications found in 15.2% of patients). Perioperative antibiotic eye drops of 0.5% levofloxacin solution provide a high level prevention of bacterial infection prevention after phacoemulsification. Patients treated with a combination of dexamethasone 0.1% solution eye drops and non-steroidal drug Broxinac had the lowest rate of postoperative inflammatory complications (7.0%).

Full Text

Restricted Access

About the authors

Yuriy I Pirogov

Medical center «Admiraltejskie verfi»

Email: oft@verficlinic.ru
MD, ophthalmologist, head of ophthalmology department

Galina M Butina

Medical center «Admiraltejskie verfi»

Email: Aleksandrbutin@mail.ru
MD, ophthalmologist

Roman A Morozov

Medical center «Admiraltejskie verfi»

Email: rmorozov@yandex.ru
MD, ophthalmologist

Aleksandr A Oksentyuk

Medical center «Admiraltejskie verfi»

Email: os753@yandex.ru
MD, ophthalmologist

Mar’yana V Rybina

Medical center «Admiraltejskie verfi»

Email: riba1208@rambler.ru
MD, ophthalmologist

Madina R Chshieva

Medical center «Admiraltejskie verfi»

Email: chshieva.madi@mail.ru
MD, ophthalmologist

Mikhail S Shatalov

Medical center «Admiraltejskie verfi»

Email: shatalov.mikhail@inbox.ru
MD, ophthalmologist


  1. Малюгин Б.Э., Шпак А.А., Морозова Т.А. Фармакологическое сопровождение современной хирургии катаракты. 3-е издание. - М.: Офтальмология, 2014. - 200 с. [Malyugin BE, Shpak AA, Morozova TA. Farmakologicheskoe soprovozhdenie sovremennoi khirurgii katarakty. 3th ed. Moscow: Oftal’mologiya; 2014. 200 p.]
  2. Пирогов Ю.И., Бутина Г.М., Оксентюк А.А., Чшиева М.Р. Сравнительный анализ различных схем профилактики инфекционных осложнений при факоэмульсификации // Катарактальная и рефракционная хирургия. - 2011. - Т. 11. - № 3. - С. 52-53. [Pirogov YI, Butina GM, Oksentyuk AA, Chshieva MR. The comparative analysis of treatment regimen for infectious complications prophylaxis at phacoemulsification. Journal Cataract and Refractive Surgery. 2011;11(3):52-53. (In Russ).]
  3. Поляк М.С. Антибиотикотерапия проблемных инфекций (преодоление резистентности). СПб.: Нестор-История, 2015. -
  4. с. [Polyak MS. Antibiotikoterapiya problemnykh infektsii (preodolenie rezistentnosti). Saint Petersburg: Nestor-Istoriya; 2015. 488 p. (In Russ).]
  5. American Academy of Ophthalmology Cataract and Anterior Segment Panel. Preferred Practice Pattern® Guidelines. Cataract in the Adult Eye. San Francisco, CA: American Academy of Ophthalmology; 2011.
  6. Kutty PK, Forster TS, Wood-Koob C, et al. Multistate outbreak of toxic anterior segment syndrome, 2005. J Cataract Refract Surg. 2008;34:585-590. doi: 10.1016/j.jcrs.2007.11.037.



Abstract - 747

PDF (Russian) - 392


Article Metrics

Metrics Loading ...



Copyright (c) 2016 Pirogov Y.I., Butina G.M., Morozov R.A., Oksentyuk A.A., Rybina M.V., Chshieva M.R., Shatalov M.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies